66548-54-7

Usage

InChI:InChI=1/C11H6ClN3/c12-11-6-5-10(14-15-11)9-3-1-8(7-13)2-4-9/h1-6H

Upstream product

• 135034-10-5 3-chloro-6-iodopyridazine 
• 36725-37-8 6-(4-bromophenyl)-4,5-dihydropyridazin-3(2H)-one 
• 50636-57-2 6-(4-bromophenyl)-3(2H)-pyridazin-3-one 
• 52240-10-5 4-(1,6-dihydro-6-oxo-3-pyridazinyl)benzonitrile 

Downstream Products

• 67821-02-7 4-[4-methyl-6-(N-methyl-hydrazino)-pyridazin-3-yl]-benzonitrile 
• 67820-75-1 N'-[6-(4-cyano-phenyl)-pyridazin-3-yl]-hydrazinecarboxylic acid ethyl ester 
• 67820-85-3 N'-[6-(4-cyano-phenyl)-5-methyl-pyridazin-3-yl]-hydrazinecarboxylic acid tert-butyl ester 
• 149354-16-5 (3R,5S)-3-Allyl-5-[[6-(4-cyanophenyl)-3-pyridazinyl]oxymethyl]-1-(3-phenylpropyl)-2-pyrrolidinone 

Relevant academic research and scientific papers

Synthesis and Bioevaluation of 3,6-Diaryl-[1,2,4]triazolo[4,3-b] Pyridazines as Antitubulin Agents

A series of 3,6-diaryl-[1,2,4]triazolo[4,3-b]pyridazines were designed as a class of vinylogous CA-4 analogues. The easily isomerized (Z,E)-butadiene linker of vinylogous CA-4 was replaced by a rigid [1,2,4]triazolo[4,3-b]pyridazine scaffold. Twenty-one target compounds were synthesized and exhibited moderate to potent antiproliferative activity. The compound 4q with a 3-amino-4-methoxyphenyl moiety as the B-ring, comparable to CA-4 (IC50 = 0.009-0.012 μM), displayed the highly active antiproliferative activity against SGC-7901, A549, and HT-1080 cell lines with IC50 values of 0.014, 0.008, and 0.012 μM, respectively. Tubulin polymerization experiments indicated that 4q effectively inhibited tubulin polymerization, and immunostaining assay revealed that 4q significantly disrupted tubulin microtubule dynamics. Moreover, cell cycle studies revealed that compound 4q dramatically arrested cell cycle progression at G2/M phase in A549 cells. Molecular modeling studies showed that 4q could bind to the colchicine binding site on microtubules.

Pd-catalyzed chemoselective cross-coupling reaction of triaryl- or triheteroarylbismuth compounds with 3,6-dihalopyridazines

The cross-coupling reactions of 3,6-dihalopyridazines with triaryl- or triheteroarylbismuth compounds were performed under palladium catalysis. The reaction was highly chemoselective, affording functionalized aryl- or heteroarylpyridazinyl chlorides in moderate to good yields. The cross-coupling reactions of 3,6-dihalopyridazines with triaryl- or triheteroarylbismuth compounds were performed under palladium catalysis. The reaction was highly chemoselective, affording functionalized aryl- or heteroarylpyridazinyl chlorides in moderate to good yields. Copyright

2-pyrrolidinones, pharmaceutical compositions containing these compounds and processes for preparing them

The invention relates to cyclic imino derivatives of general formula wherein A, B, E, X2 to X5 and Y are defined as in claim 1, the stereoisomers, tautomers, mixtures and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable pharmacological properties, preferably aggregation-inhibiting effects, pharmaceutical compositions which contain these compounds and processes for preparing them.

Heterobiarly derivatives and pharmaceutical compositions thereof

Heterobiaryl derivatives of the formula wherein R1, X1 to X3 and Y1 to Y4 are as defined herein, the tautomers, stereoisomers and mixtures thereof, and the salts, particularly the physiologica

Hypotensive alkyl-3-[6-(aryl)-3-pyridazinyl]-carbazates

This disclosure describes novel alkyl 3-[6-(aryl)-3-pyridazinyl]-carbazates useful as hypotensive agents in mammals. SP CROSS REFERENCE TO RELATED APPLICATIONS This application is a continuation of our copending application Ser. No. 692,254, filed June 3, 1976 now abandoned, which in turn is a continuation-in-part of our abandoned application Ser. No. 552,024, filed Feb. 24, 1975 now abandoned.